Clinical Combo Trial Recruiting

This moderated forum is to support the needs of patients with stage IV melanoma, as well as to answer questions about treatment options and what to expect.

Clinical Combo Trial Recruiting

Postby Catherine Poole » Tue Oct 17, 2017 10:04 am

A Phase 2 clinical trial called IMO-2125-204, NCT02644967, for the treatment of patients with advanced melanoma. The IMO-2125-204 clinical trial will evaluate the treatment of IMO-2125 (an investigational drug) in combination with either ipilimumab (Yervoy®) or pembrolizumab (Keytruda®). If you, or someone you know, has been diagnosed with an advanced form of metastatic melanoma (melanoma that has spread to other parts of the body) for whom treatment has failed with Keytruda® (pembrolizumab) or Opdivo® (nivolumab), you may be eligible to participate in the IMO-2125-204 clinical trial. For more information about the trial, please visit
clinicaltrials.gov/NCT02644967
Catherine M. Poole, President/Founder
Melanoma International Foundation
Catherine Poole
 
Posts: 10782
Joined: Wed Jan 02, 2008 12:09 am

Re: Clinical Combo Trial Recruiting

Postby Catherine Poole » Thu Nov 09, 2017 10:20 am

This trial is for measurable, stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease. The agent is injected into the tumor, so it must be in reach or an intransit met. Then it is combined with either IPI in one arm or PD1 in the other arm of it.
Catherine M. Poole, President/Founder
Melanoma International Foundation
Catherine Poole
 
Posts: 10782
Joined: Wed Jan 02, 2008 12:09 am


Return to Melanoma Diagnosis: Stage IV

Who is online

Registered users: Bing [Bot], Google [Bot]